109 related articles for article (PubMed ID: 25639617)
21. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
[TBL] [Abstract][Full Text] [Related]
22. Sunitinib effective for rare thymus cancer.
Cancer Discov; 2015 Apr; 5(4):340. PubMed ID: 25680712
[TBL] [Abstract][Full Text] [Related]
23. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
Mena AC; Pulido EG; Guillén-Ponce C
Anticancer Drugs; 2010 Jan; 21 Suppl 1():S3-11. PubMed ID: 20110785
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
Saltz LB; Rosen LS; Marshall JL; Belt RJ; Hurwitz HI; Eckhardt SG; Bergsland EK; Haller DG; Lockhart AC; Rocha Lima CM; Huang X; DePrimo SE; Chow-Maneval E; Chao RC; Lenz HJ
J Clin Oncol; 2007 Oct; 25(30):4793-9. PubMed ID: 17947727
[TBL] [Abstract][Full Text] [Related]
25. Pharmacia's SU5416 not effective.
Expert Rev Anticancer Ther; 2002 Feb; 2(1):5. PubMed ID: 12113066
[No Abstract] [Full Text] [Related]
26. Alveolar soft part sarcoma in childhood: is Sunitinib-Sutent® treatment an effective approach?
Hilbert M; Mary P; Larroquet M; Serinet MO; Helfre S; Brisse H; Coulomb A; Orbach D
Pediatr Blood Cancer; 2012 Mar; 58(3):475-6. PubMed ID: 22234817
[No Abstract] [Full Text] [Related]
27. Epithelioid hemangioendothelioma of the kidney treated with sunitinib.
Tolkach Y; Petrov S; Lerut E; Van Poppel H
Onkologie; 2012; 35(6):376-8. PubMed ID: 22722460
[TBL] [Abstract][Full Text] [Related]
28. Antiangiogenic therapy for von Hippel-Lindau disease.
Madhusudan S; Deplanque G; Braybrooke JP; Cattell E; Taylor M; Price P; Tsaloumas MD; Moore N; Huson SM; Adams C; Frith P; Scigalla P; Harris AL
JAMA; 2004 Feb; 291(8):943-4. PubMed ID: 14982909
[No Abstract] [Full Text] [Related]
29. New perspectives: role of Sunitinib in breast cancer.
Fratto ME; Imperatori M; Vincenzi B; Tomao F; Santini D; Tonini G
Clin Ter; 2011; 162(3):251-7. PubMed ID: 21717054
[TBL] [Abstract][Full Text] [Related]
30. Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: Involvement of eradicating cancer stem-like cells.
Wang S; Mou Z; Ma Y; Li J; Li J; Ji X; Wu K; Li L; Lu W; Zhou T
Biochem Pharmacol; 2015 May; 95(2):98-109. PubMed ID: 25824241
[TBL] [Abstract][Full Text] [Related]
31. [Clinical observation of sunitinib treatment for refractory advanced breast cancer ulcer].
Zhao X; Meng XY; Sun B; Ding LJ; Jiang ZF; Song ST; Wu SK
Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(2):96-8. PubMed ID: 23648343
[TBL] [Abstract][Full Text] [Related]
32. Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib.
Maeng CH; Yi JH; Lee J; Hong JY; Choi MK; Jung HA; Park JO; Park SH; Park YS; Kang WK; Lim HY
Anticancer Res; 2013 Oct; 33(10):4619-26. PubMed ID: 24123039
[TBL] [Abstract][Full Text] [Related]
33. Suppressing effects of sunitinib on allergic rhinitis: previously undefined side effects with therapeutic potential.
Eechoute K; van Zonneveld M; van Daele PL; van Wijk RG; Mathijssen RH
J Clin Pharmacol; 2011 Nov; 51(11):1592-5. PubMed ID: 21189307
[No Abstract] [Full Text] [Related]
34. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
35. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
36. New perspectives: role of sunitinib in breast cancer.
Fratto ME; Imperatori M; Vincenzi B; Tomao F; Santini D; Tonini G
Clin Ter; 2010; 161(5):475-82. PubMed ID: 20949248
[TBL] [Abstract][Full Text] [Related]
37. [Sunitinib and hypothyroidism].
Cohen R; Bihan H; Uzzan B; des Guetz G; Krivitzky A
Ann Endocrinol (Paris); 2007 Oct; 68(5):332-6. PubMed ID: 17707761
[TBL] [Abstract][Full Text] [Related]
38. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
39. The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects.
Seandel M; Shia J; Linkov I; Maki RG; Antonescu CR; Dupont J
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6203-4. PubMed ID: 17062698
[No Abstract] [Full Text] [Related]
40. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.
Castellano D; González-Larriba JL; Antón-Aparicio LM; Cassinello J; Grande E; Esteban E; Sepúlveda J
Expert Opin Pharmacother; 2011 Nov; 12(16):2433-9. PubMed ID: 21671835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
